ERBB2 and breast carcinoma: In another recent study, single-photon emission computed tomography (SPECT) imaging revealed that anti-VEGF treatment decreased tumor uptake of an anti-Her2 antibody (trastuzumab) in preclinical breast cancer models, thus further supporting that VEGF blockade results in decreased tumor perfusion rather than vessel normalization [15].